Navigation Links
PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy

al data, we plan to initiate longer-term clinical trials to evaluate the clinical benefit of PTC124 in patients with DMD."

The Phase 2 clinical trial is being conducted at three sites in the United States: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; and the University of Utah, Salt Lake City, Utah. In the study, patients have received 28 days of PTC124 treatment at one of three dose levels. All clinical trial participants are boys with a nonsense mutation in the dystrophin gene, substantially elevated serum creatine kinase levels, and symptoms associated with DMD. The analysis presented today includes data from 26 patients with DMD who received PTC124 at the low-dose and medium-dose levels. Completion of accrual and analysis of data from a higher dose level are ongoing.

The primary endpoint of the trial has been the proportion of patients having an increase in dystrophin expression in muscle during 28 days of treatment with PTC124. Pre- and post-treatment muscle biopsies were available from all 26 patients for analysis. In vitro treatment of patient muscle cells with PTC124 showed evidence of a dose-dependent increase in dystrophin expression in all of the evaluable patients. Preliminary review of the data indicate that, at both dose levels evaluated in this analysis, approximately half of the patients demonstrated visible improvement in the staining for muscle dystrophin in vivo. Overall, four of the six, or 67 percent, of patients treated at the lower dose level and 10 of the 20, or 50 percent, of patients treated at the medium dose level demonstrated an increase in the expression of dystrophin post-treatment. Response did not appear to be dependent on type of nonsense mutation.

Additionally, statistically significant reductions in the concentrations of muscle-derived creatine kinase levels in the blood were observed during PTC124 treatment. Several parents a
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:1/23/2015)... 23, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... the development and sale of patented biopharmaceutical medicine, modernized ... ingredients (API) today announced the business and development progress ... 1. Following the September 2014 JCM application (No. ...
(Date:1/22/2015)... 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the ... therapies for cardiovascular disease and overall health is pleased to ... 2014 and its outlook for 2015 from the CEO, Mr. ... We would like to take this opportunity to share ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/3h534b/infectious ) has announced ... by Product, Application, Technology, End User - Global Forecast ... The infectious disease diagnostics market is expected to ... by 2019 from $12,422.8 million in 2014. Increase in ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3
... , , LAWRENCE, Mass., Dec. ... battle for improved comfort and overall patient satisfaction in ... are measuring the positive effects of OBP Medical,s Under ... stay. A hospital wide survey is comparing patients, perception ...
... , , EXTON, Pa., Dec. 14 BioTrends ... a syndicated publication offering comprehensive insight into the management ... comparison of self-reported treatment approaches (as reported by 208 Rheumatologists) ... who are currently being treated with biologic agents. , To ...
Cached Medicine Technology:Under Johnnies(TM) Proven To Increase Patient Satisfaction by OBP Medical Inc. 2New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis 2New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis 3
(Date:1/22/2015)... California (PRWEB) January 22, 2015 The City of ... at 10 a.m., to commemorate the 42nd anniversary of the Supreme ... States. , “It’s been 42 years since the Roe vs. Wade ... is still as present as ever,” said City of West Hollywood ...
(Date:1/22/2015)... Chemo Duck Program is pleased to announce the release of the ... with cancer. The Chemo Duck App, available on iTunes for use ... to help children of all ages living with cancer adjust to ... entertained, educated and at ease while waiting for clinic visits or ...
(Date:1/22/2015)... a seasoned and trusted leader who consistently delivers trendy dresses ... it lead the wedding dress industry into the future. Today, ... the global market. , “The CEO of VogueQueen is uniquely ... continuing the goal of operational excellence and giving back to ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many trendy ... on Facebook, Twitter, and Pinterest. The fans will have an ... lottery every week. , Moreover, the company has extended its ... Angelweddingdress homepage for more information. , Angelweddingdress is ...
(Date:1/22/2015)... 23, 2015 AngelWeddingDress, the premier women’s ... maternity wedding dresses. View website of AngelWeddingDress.com ... for maternity wedding dresses online for a bridal party. ... high quality for them. Its maternity wedding dresses are ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2
... Mozes HealthDay Reporter , MONDAY, Dec. 6 ... psychotherapy for their depression, antidepressant prescription rates have ... reveals. "This is an encouraging trend as it ... said study author Dr. Mark Olfson, a professor of ...
... , MONDAY, Dec. 6 (HealthDay News) -- Long-term ... of dying from a wide array of cancers, a new ... that a low-dose aspirin (75 milligrams) taken daily for at ... percent drop in fatalities depending on the type of cancer. ...
... in the December issue of The Journal of ... scans as a potentially useful tool for predicting local ... (RFA). RFA, which uses localized thermal energy to kill ... for patients unable to undergo surgery or other therapies ...
... process of making, distributing and administering millions of ... could design a vaccine that confers decades-long protection ... universal influenza vaccine is feasible but licensing it ... new ways to evaluate the efficacy of vaccine ...
... HealthDay Reporter , MONDAY, Dec. 6 (HealthDay News) -- Applying sunscreen ... chances of getting melanoma by half, a new study has found. ... 25 to 75 into two groups. One group was told to ... for five years between 1992 and 1996. The other group was ...
... Dec. 6 (HealthDay News) -- Women who experience restless ... for having it again during future pregnancies or developing ... researchers have found. RLS causes unpleasant sensations in ... tend to progress with age. Movement generally relieves symptoms. ...
Cached Medicine News:Health News:Antidepressant Use Rising as Psychotherapy Rates Fall 2Health News:Antidepressant Use Rising as Psychotherapy Rates Fall 3Health News:Daily Aspirin Linked to Steep Drop in Cancer Risk 2Health News:Daily Aspirin Linked to Steep Drop in Cancer Risk 3Health News:Fewer guessing games for lung cancer patients 2Health News:A flu vaccine that lasts 2Health News:Daily Sunscreen Use Does Protect from Melanoma, Study Finds 2Health News:Daily Sunscreen Use Does Protect from Melanoma, Study Finds 3Health News:Restless Legs in Pregnancy Likely to Recur, Researchers Say 2
Anti-MPO ANCA EIA Auto-Immune Markers 013-MPO-96 Myeloperoxidase...
... the quantitative determination of Immunoglobulin E ... atopic allergic diseases such as atopic ... been shown to exhibit increased total,immunoglobulin ... is also known as the,reagenic antibody. ...
... Complexes from patient serum or plasma, standards and ... microtiter wells. After a washing step, an ... to the Fc region of human IgG. ... pipetted followed by a stopping step. The ...
... captured with the CR-DGi can be viewed immediately, ... the beginning. Because the images are digital, ... such as telemedicine and electronic filing. The ... quality and ease of use. It's the latest ...
Medicine Products: